Business Wire

XPRIZE and Musk Foundation Name 23 Winners in Five Million Dollar Carbon Removal Student Competition

10.11.2021 15:00:00 EET | Business Wire | Press release

Share

XPRIZE , the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges, today announced that 23 student-led teams have won the $5M Carbon Removal Student Competition. The award program, which is part of the $100 Million XPRIZE for Carbon Removal supported by the Musk Foundation, was launched, in part, to fund early stage concepts from the next generation of carbon removal innovators and to remove barriers to entry for those interested in the main competition.

Competing student teams had the opportunity to submit their concepts for an award in one of two tracks, Carbon Dioxide Removal Demonstrations or Measurement, Reporting, and Verification Technologies . Winning student teams are able to use funds to compete in subsequent rounds of XPRIZE Carbon Removal or to develop key supporting technologies which will enable carbon dioxide removal. Points of focus for the two award tracks were as follows:

  • Carbon Dioxide Removal Demonstrations: Awards of US$250,000 to student teams intending to compete for the XPRIZE Carbon Removal Milestone and Grand Prize awards across the various carbon removal pathways: Air, Land, Rocks, Oceans. Teams needed to convince the judges that their proposed carbon removal projects would make them competitive applicants in the overall competition. This was the main focus of the Student Awards; the majority of awards are in this category.
  • Measurement, Reporting, and Verification Technologies: Awards of US$100,000 for the development of technologies that may not directly remove CO2, but will enable carbon removal. Technologies or methodologies for improving the standards of assessment, or the precision, accuracy, and time required for carbon measurements were considered.

Representing ten countries and 31 international educational institutions, the winners of the Carbon Removal Student Competition, included:

Student Carbon Removal Demonstrations:

  • Answer of Biochar (AOB) from Northeastern University, China (China)
  • E-quester from the University of Toronto (Canada)
  • BioCORE from the University of Munich (Germany)
  • Biosorra from IESE Business School and the Fuqua School of Business (Spain & United States)
  • Bison Underground affiliated with the University of Oklahoma (United States)
  • Blue Symbiosis from the University of Tasmania IMAS AMC (Australia)
  • C2 (C-Squared) from Virginia Tech and the Max Planck Institute for Biogeochemistry (Germany & United States)
  • Carbon Down Under from Southern Illinois University, Carbondale (United States)
  • CyanoCapture from the University of Oxford (United Kingdom)
  • Holocene Climate from Stanford University (United States)
  • KFC from Hohai University, Tianjin University, Shanghai Ocean University, and Chinese Academy of Fishery Sciences (China)
  • Mississippi State Energy Club - BECReative Energy from Mississippi State University (United States)
  • Monash Carbon Capture and Conversion (BioTech) from Monash University (Australia & Malaysia)
  • SASIITB from Indian Institute of Technology, Bombay (India)
  • Skyrenu Technologies from Université De Sherbrooke and Inrs-Eau Terre Environnement Research Centre (Canada)
  • Sydney Sustainable Carbon from the University of Sydney (Australia)
  • Takachar (Safi Organics) from the University of British Columbia, Northeastern University and IISC Bangalore (Canada, India, Kenya & United States)
  • UW-Madison Civil and Environmental Engineering from the University of Wisconsin, Madison (United States)

Measurement, Reporting, and Verification Technologies:

  • ACIDD Project from the University of Miami (United States)
  • BJU Global Challenges from Bob Jones University (United States)
  • Environmental Sensing from the University of Wyoming (United States)
  • PlantVillage from Pennsylvania State University (United States)
  • Working Trees from Stanford University (United States)

In order to be eligible for the Carbon Removal Student Competition, student teams needed at least 50% of their members to be currently enrolled in an educational institution with the support of an academic advisor or business leader able to act as a formal mentor. All submissions were reviewed by a panel of expert third-party judges who considered the innovation, ability to reach gigaton scale, team resources and capabilities as well as project plan feasibility in their selection process.

“We want to make a truly meaningful impact. Carbon negativity, not neutrality. The ultimate goal is scalable carbon extraction technologies that are measured based on the ‘fully considered cost per ton’ which includes the environmental impact. This is not a theoretical competition; we want teams that will build real systems that can make a measurable impact and scale to a gigaton level. Whatever it takes. Time is of the essence,” said Elon Musk, Founder and CEO of Tesla and SpaceX, in a previous statement.

Launched in April, XPRIZE Carbon Removal is a US$100M four-year global competition that invites innovators and teams from anywhere on the planet to create and demonstrate solutions that can pull carbon dioxide directly from the atmosphere or oceans. To win the grand prize, teams must demonstrate a working solution at a scale of at least 1000 tonnes removed per year; model their costs at a scale of 1 million tonnes per year; and show a pathway to achieving a scale of gigatonnes per year in future, as validated by a third party.

“Today’s college and graduate students have proclaimed that solving the climate crisis is one of the most important objectives of their generation. It’s for this reason that this student competition is so critical. Our mission is to engage, inspire and guide the next generation of climate entrepreneurs,” said Peter H. Diamandis, Founder and Executive Chairman of XPRIZE.

Any carbon negative solution is eligible: nature-based, direct air capture, oceans, mineralization, or anything else that achieves net negative emissions, sequesters CO2 durably, and shows a sustainable path to ultimately achieving gigatonne scale.

“The climate crisis is an existential threat that demands both immediate action, and a long-term commitment to bringing Earth’s carbon cycle back into balance for future generations,” said Dr. Marcius Extavour, Vice President of Climate and Environment at XPRIZE. “We’ve already begun to feel the impacts of the climate crisis in our day-to-day lives, and the data shows us that we need both immediate action on emissions reductions, and sustained innovation to develop additional tools like carbon removal. That’s why this prize is so important. It’s about mobilizing and facilitating the development of scalable solutions that can make a real difference in stabilizing the climate over the coming decades.”

For more information on XPRIZE Carbon Removal, to view the prize guidelines or to register, please visit xprize.org/carbonremoval.

About XPRIZE

XPRIZE is a global future-positive movement of over 1M people and rising, delivering truly radical breakthroughs for the benefit of humanity. XPRIZE inspires and empowers a global community of problem-solvers to positively impact our world by crowdsourcing solutions through large-scale competitions, tackling the world’s grandest challenges in exploration, environment and human equity. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1 Million Digital Learning Challenge. Donate, sign up or join a team at xprize.org.

About The Musk Foundation

The Musk Foundation creates grants made in support of: renewable energy research and advocacy; human space exploration research and advocacy; pediatric research; science and engineering education; and development of safe artificial intelligence to benefit humanity.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, 949-280-0182
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye